SPHK1 and Familial prostate cancer: These findings were similar to those obtained with the dual SK1/SK2 inhibitor, SKi, which can activate the proteasome and promote accelerated ubiquitin-proteasomal degradation of SK1a in androgen-sensitive and androgen independent LNCaP prostate cancer cells [4].